Long Noncoding RNA PXN-AS1-L Promotes Non-small Cell Lung Cancer Progression Via Regulating PXN

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2019 Jan 26

PMID 30679933

Citations 12

Authors

Zhifa Zhang

Zhaohui Peng

Junying Cao

Jiaqi Wang

Yongyu Hao

Kai Song

Yan Wang

Wei Hu

Xuesong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Increasingly evidences suggest that long noncoding RNAs (lncRNAs) play important roles in various cancers. LncRNA PXN-AS1-L is recently revealed to act as on oncogene in liver cancer. However, the expression, functions, and mechanisms of action of PXN-AS-L in non-small cell lung cancer (NSCLC) remain unclear.

Methods: The expression of PXN-AS1-L in primary NSCLC tissues, NSCLC bone metastasis tissues, and cell lines was measured by quantitative real-time PCR. The correlations between PXN-AS1-L expression and clinicopathological characteristics of NSCLC patients were analyzed by Pearson Chi square test and log-rank test. The roles of PXN-AS1-L in cell viability, proliferation, apoptosis, and migration of NSCLC cells, and in vivo NSCLC tumor growth were investigated by a series of gain-of-function and loss-of-function assays. The regulatory roles of PXN-AS1-L on PXN were determined by quantitative real-time PCR and western blot.

Results: PXN-AS1-L was up-regulated in NSCLC tissues compared with noncancerous lung tissues, and PXN-AS1-L was further up-regulated in NSCLC bone metastasis tissues. Increased expression of PXN-AS1-L was positively associated with advanced TNM stages and poor prognosis. Gain-of-function and loss-of-function assays showed that PXN-AS1-L increased cell viability, promoted cell proliferation, inhibited cell apoptosis, and promoted cell migration of NSCLC cells. Xenograft assays showed that PXN-AS1-L also promoted NSCLC tumor growth in vivo. Mechanistically, we found that PXN-AS1-L, as an antisense transcript of PXN, up-regulated the expression of PXN. PXN was also up-regulated in NSCLC tissues. The expression of PXN and PXN-AS1-L was positively correlated in NSCLC tissues. Furthermore, PXN knockdown attenuated the roles of PXN-AS1-L in increasing cell viability, promoting cell proliferation, inhibiting cell apoptosis, and promoting cell migration of NSCLC cells.

Conclusions: Our data revealed that PXN-AS1-L is up-regulated and acts as an oncogene in NSCLC via up-regulating PXN. Our data suggested that PXN-AS1-L might serve as a potential prognostic biomarker and therapeutic target for NSCLC.

Citing Articles

Long non-coding RNA PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid leukemia BCR::ABL1-independent resistance to Imatinib via cell cycle signaling pathway.

Li Y, Yuan S, Zhou Y, Zhou J, Zhang X, Zhang P Cancer Cell Int. 2024; 24(1):186.

PMID: 38811958 PMC: 11138077. DOI: 10.1186/s12935-024-03363-9.

Upregulation of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in non-functioning pituitary adenoma.

Taheri M, Safarzadeh A, Bahranian A, Eslami S, Dilmaghani N, Ghafouri-Fard S J Cell Mol Med. 2023; 27(11):1550-1556.

PMID: 37154079 PMC: 10243150. DOI: 10.1111/jcmm.17763.

Long non-coding RNAs in bone metastasis: progresses and perspectives as potential diagnostic and prognostic biomarkers.

Maroni P, Gomarasca M, Lombardi G Front Endocrinol (Lausanne). 2023; 14:1156494.

PMID: 37143733 PMC: 10153099. DOI: 10.3389/fendo.2023.1156494.

Long Noncoding RNA LEMD1-AS1 Increases LEMD1 Expression and Activates PI3K-AKT Pathway to Promote Metastasis in Oral Squamous Cell Carcinoma.

Li Z, Wang J, Wu J, Li N, Jiang C Biomed Res Int. 2022; 2022:3543948.

PMID: 35983249 PMC: 9381283. DOI: 10.1155/2022/3543948.

Regulation of apoptosis, autophagy and ferroptosis by non-coding RNAs in metastatic non-small cell lung cancer (Review).

Xu L, Huang X, Lou Y, Xie W, Zhao H Exp Ther Med. 2022; 23(5):352.

PMID: 35493430 PMC: 9019694. DOI: 10.3892/etm.2022.11279.

References

Liu S, Thomas S, Woodside D, Rose D, Kiosses W, Pfaff M . Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature. 1999; 402(6762):676-81. DOI: 10.1038/45264. View

Huang C, Rajfur Z, Borchers C, Schaller M, Jacobson K . JNK phosphorylates paxillin and regulates cell migration. Nature. 2003; 424(6945):219-23. DOI: 10.1038/nature01745. View

Ponting C, Oliver P, Reik W . Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41. DOI: 10.1016/j.cell.2009.02.006. View

Zhang L, Yang F, Yuan J, Yuan S, Zhou W, Huo X . Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2012; 34(3):577-86. DOI: 10.1093/carcin/bgs381. View

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G . The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2012; 73(3):1180-9. PMC: 3589741. DOI: 10.1158/0008-5472.CAN-12-2850. View

Xu D, Yang F, Yuan J, Zhang L, Bi H, Zhou C . Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/β-catenin signaling. Hepatology. 2013; 58(2):739-51. DOI: 10.1002/hep.26361. View

Batista P, Chang H . Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013; 152(6):1298-307. PMC: 3651923. DOI: 10.1016/j.cell.2013.02.012. View

Flintoft L . Non-coding RNA: Structure and function for lncRNAs. Nat Rev Genet. 2013; 14(9):598. DOI: 10.1038/nrg3561. View

Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View

10.

Bi Y, Han Y, Bi H, Gao F, Wang X . miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin. Hum Cell. 2013; 27(3):95-102. DOI: 10.1007/s13577-013-0085-4. View

11.

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

12.

Sun M, Liu X, Wang K, Nie F, Kong R, Yang J . Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer. 2014; 13:68. PMC: 3998010. DOI: 10.1186/1476-4598-13-68. View

13.

Yuan J, Yang F, Wang F, Ma J, Guo Y, Tao Q . A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014; 25(5):666-81. DOI: 10.1016/j.ccr.2014.03.010. View

14.

Chen Z, Fillmore C, Hammerman P, Kim C, Wong K . Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8):535-46. PMC: 5712844. DOI: 10.1038/nrc3775. View

15.

White N, Cabanski C, Silva-Fisher J, Dang H, Govindan R, Maher C . Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014; 15(8):429. PMC: 4156652. DOI: 10.1186/s13059-014-0429-8. View

16.

Mizrahi I, Mazeh H, Grinbaum R, Beglaibter N, Wilschanski M, Pavlov V . Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach. J Cancer. 2015; 6(2):105-10. PMC: 4280392. DOI: 10.7150/jca.10568. View

17.

Iyer M, Niknafs Y, Malik R, Singhal U, Sahu A, Hosono Y . The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015; 47(3):199-208. PMC: 4417758. DOI: 10.1038/ng.3192. View

18.

Wu D, Chen C, Chu C, Lee H . Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability. Oncogene. 2015; 35(5):621-30. DOI: 10.1038/onc.2015.120. View

19.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao S . Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell. 2015; 28(4):529-540. PMC: 4777353. DOI: 10.1016/j.ccell.2015.09.006. View

20.

Lin A, Li C, Xing Z, Hu Q, Liang K, Han L . The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol. 2016; 18(2):213-24. PMC: 4791069. DOI: 10.1038/ncb3295. View